Evonik, one of the world’s leading specialty chemicals companies, has named Guido Skudlarek President of the North America region effective June 1, 2024, adding top-level management expertise to its local leadership team. Bonnie Tully, who led the region since 2020, becomes Chief Operations Officer for North America, focusing on the region’s broad footprint of production sites and new business developments.

“North America has become a crucial growth region for Evonik,” says Chief Financial Officer Maike Schuh, the Evonik management board member responsible for the Americas. “I am excited that Guido and Bonnie will contribute their unique skill sets to the next phase of our growth trajectory in the United States, Canada, and Mexico.”

Skudlarek most recently served as Head of Operations Excellence at the company’s headquarters in Essen, Germany, designing and implementing global transformation programs in production and supply chain management. He previously headed specialties within Evonik’s silica business and advanced its overall growth strategy. This included managing the antitrust review process for the acquisition of U.S.-based J.M. Huber Corp.’s silica business.

Skudlarek studied business administration and engineering in Germany and the U.K. and holds a doctorate from the University of Bayreuth, Germany. He began his professional career in 2001 at the consulting firm McKinsey & Company before joining Evonik in 2013. “I am looking forward to working with the region’s excellent team to expand Evonik’s business in North America,” says Skudlarek.

Tully, who studied mechanical engineering at Texas A&M, has more than 30 years of experience at Evonik and its predecessors. She will oversee the expanding operations in a region that recorded €3.8 billion in revenue in fiscal 2023, a quarter of the Group’s total. “I am an engineer at heart, and I can’t wait to again dive into the operational details of our great company.” Tully is also the Executive Sponsor of groW Americas, the women’s Employee Resource Group at Evonik.